Masur Auditorium – NIH Campus
March 26, 2015
Intraocular inflammation is associated with many complications, including glaucoma, cataracts, macular edema, retinal vascular occlusion and blindness. There is a need for new, more effective corticosteroid sparing anti-inflammatory agents.
This one-day public workshop reviewed clinical trial design considerations for inflammatory eye disease in order to develop strategies for:
- Improved trial design and endpoints based on current evidence
- Approaches to classifying and stratifying the patient population
- Clinically meaningful surrogate or interim endpoints
- Potentially impactful gaps for research funding